Regencell Bioscience (NASDAQ:RGC) Posts Earnings Results

Regencell Bioscience (NASDAQ:RGC) announced its quarterly earnings results on Friday. The company reported $0.00 earnings per share for the quarter, FiscalAI reports.

Regencell Bioscience Stock Performance

RGC opened at $29.28 on Friday. Regencell Bioscience has a 12 month low of $6.13 and a 12 month high of $83.60. The stock’s 50 day moving average price is $27.18 and its 200 day moving average price is $23.85.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Regencell Bioscience News Roundup

Here are the key news stories impacting Regencell Bioscience this week:

• Positive Sentiment: Regencell reported quarterly EPS of $0.00, which removes near-term earnings disappointment, though it does not provide a strong growth catalyst. MarketBeat earnings report
• Neutral Sentiment: Multiple law firms reiterated deadlines for investors in an existing class action tied to Regencell securities purchased between October 28, 2024 and October 31, 2025. These notices mainly update shareholders on legal options rather than company operations. Pomerantz class action filing
• Neutral Sentiment: Other firms, including Rosen, Schall, Faruqi & Faruqi, and Glancy Prongay Wolke & Rotter, continued reminding investors of the June 23, 2026 lead-plaintiff deadline, adding to legal overhang but not introducing new operational news. Schall Law Firm notice
• Negative Sentiment: The biggest drag on RGC appears to be the ongoing securities-fraud litigation and related investor-loss marketing, which can weigh on sentiment and increase uncertainty around the stock. Robbins LLP notice

Institutional Trading of Regencell Bioscience

Large investors have recently added to or reduced their stakes in the business. Seven Fleet Capital Management LP acquired a new stake in Regencell Bioscience in the 4th quarter valued at approximately $92,000. Hudson Bay Capital Management LP acquired a new stake in Regencell Bioscience in the 4th quarter valued at approximately $275,000. Vident Advisory LLC increased its position in Regencell Bioscience by 65.7% in the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after acquiring an additional 11,866 shares during the period. XTX Topco Ltd acquired a new stake in Regencell Bioscience in the 3rd quarter valued at approximately $598,000. Finally, BNP Paribas Financial Markets acquired a new stake in Regencell Bioscience in the 2nd quarter valued at approximately $768,000. 0.13% of the stock is currently owned by institutional investors and hedge funds.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.